The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients
Open accessAbstract
Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 7×
“One such potential pharmacological approach is the use of immunomodulators in the subset of patients who develop a cytokine storm associated with pulmonary involvement including ARDS that leads to a rapid deterioration of the co-morbid conditions in such patients (Appendix Fig S1; Huang et al , 2020; Siddiqi & Mehra,…”
BackgroundInfluentialZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,344
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.013 · Cited by 5,028
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)
Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, L., Zheng, D., Wang, J., Hesketh, R. L., Yang, L., et al. (2020) · Radiology · doi:10.1148/radiol.2020200370 · Cited by 2,856
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · cited 1×
“RNA was extracted using Direct-zol Mini Kit (Zymo Research), and relative level of viral RNA was determined by qRT – PCR as previously described (Monteil et al , 2020).”
MethodSelf-citationCOVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701
COVID-19 infection: the perspectives on immune responses
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., Bucci, E., Piacentini, M., Ippolito, G., & Melino, G. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0530-3 · Cited by 1,594
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Self-citationCOVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Self-citationLung pathology of fatal severe acute respiratory syndrome
Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., Chu, C. M., Hui, P. K., Mak, K. L., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13413-7 · Cited by 1,076
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
The European Centre for Disease Prevention and Control
Gouvras, G. (2004) · Eurosurveillance · doi:10.2807/esm.09.10.00478-en · Cited by 741
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 3×
“Cryopreserved PHH (BioIVT, USA) was thawed and seeded into 96-well ultra-low attachment plates (Corning) with 1,500 cells per well as previously described (Bell et al , 2016).”
BackgroundMethodSelf-citationAn interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98814 · Cited by 536
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00527-07 · Cited by 386
Inoue, Y., Tanaka, N., Tanaka, Y., Inoue, S., Morita, K., Zhuang, M., Hattori, T., & Sugamura, K. (2007) · Journal of Virology · doi:10.1128/jvi.00253-07 · Cited by 369
McInnes, I. B., Byers, N. L., Higgs, R. E., Lee, J., Macias, W. L., Na, S., Ortmann, R. A., Rocha, G., Rooney, T. P., Wehrman, T., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1964-1 · Cited by 281
Self-citationBekerman, E., Neveu, G., Shulla, A., Brannan, J., Pu, S.-Y., Wang, S., Xiao, F., Barouch-Bentov, R., Bakken, R. R., Mateo, R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89857 · Cited by 226
Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 222
Chaudhuri, R., Lindwasser, O. W., Smith, W. J., Hurley, J. H., & Bonifacino, J. S. (2007) · Journal of Virology · doi:10.1128/jvi.02725-06 · Cited by 214
Baricitinib for COVID-19: a suitable treatment?
Favalli, E. G., Biggioggero, M., Maioli, G., & Caporali, R. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30262-0 · Cited by 213
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Self-citationExpression of Lymphocytes and Lymphocyte Subsets in Patients with Severe Acute Respiratory Syndrome
Cui, W., Fan, Y., Wu, W., Zhang, F., Wang, J., & Ni, A. (2003) · Clinical Infectious Diseases · doi:10.1086/378587 · Cited by 180
Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Self-citationEarly events during human coronavirus OC43 entry to the cell
Owczarek, K., Szczepański, A., Milewska, A., Baster, Z., Rajfur, Z., Sarna, M., & Pyrć, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-25640-0 · Cited by 138
Neveu, G., Ziv-Av, A., Barouch‐Bentov, R., Berkerman, E., Mulholland, J., & Einav, S. (2015) · Journal of Virology · doi:10.1128/jvi.02705-14 · Cited by 135
Tanaka, Y., Emoto, K., Cai, Z., Aoki, T., Schlichting, D. E., Rooney, T. P., & Macias, W. L. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150613 · Cited by 124
Self-citationGenovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G. R., Brinker, D. R., Rooney, T. P., Zhong, J., Mo, D., Saifan, C., Cardoso, A., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30032-1 · Cited by 85
Self-citationOpen source clinical science for emerging infections
Dunning, J. W., Merson, L., Rohde, G. G. U., Gao, Z., Semple, M. G., Tran, D., Gordon, A. C., Olliaro, P., Khoo, S., Bruzzone, R., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70327-x · Cited by 84
Baricitinib for COVID-19: a suitable treatment? – Authors' reply
Richardson, P. J., Corbellino, M., & Stebbing, J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30270-x · Cited by 71
Self-citationOliva‐Vilarnau, N., Vorrink, S. U., Ingelman‐Sundberg, M., & Lauschke, V. M. (2020) · Advanced Science · doi:10.1002/advs.202000248 · Cited by 63
Self-citationWinthrop, K. L., Bingham, C. O., Komocsar, W. J., Bradley, J., Issa, M., Klar, R., & Kartman, C. E. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1883-1 · Cited by 61
Tanaka, Y., McInnes, I. B., Taylor, P. C., Byers, N. L., Chen, L., de Bono, S., Issa, M., Macias, W. L., Rogai, V., Rooney, T. P., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40680 · Cited by 40
Self-citationGenovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G. R., Brinker, D. R., Rooney, T. P., Zhong, J., Mo, D., Saifan, C., Cardoso, A., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-eular.691 · Cited by 29
Self-citationWhat Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials
Ottaviani, S., & Stebbing, J. (2020) · Med · doi:10.1016/j.medj.2020.04.002 · Cited by 8
Self-citation
Cited by
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,835
Self-citationSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Self-citationMarconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 695
Self-citationSARS-CoV-2 detection, viral load and infectivity over the course of an infection
Walsh, K. A., Jordan, K., Clyne, B., Rohde, D., Drummond, L., Byrne, P., Ahern, S., Carty, P. G., O'Brien, K. K., O'Murchu, E., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.067 · Cited by 608
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Metadata
- Authors
- Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V., Lauschke, V. M., Mirazimi, A., Youhanna, S., Tan, Y., Baldanti, F., Sarasini, A., Terres, J. A. R., Nickoloff, B. J., Higgs, R. E., Rocha, G., Byers, N. L., Schlichting, D. E., Nirula, A., Cardoso, A., Corbellino, M., & the Sacco Baricitinib Study Group
- Venue
- EMBO Molecular Medicine
- Published
- 2020-06-24
- Volume
- 12
- Issue
- 8
- Pages
- e12697-e12697
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3029848232
- Cited by
- 291
- References
- 41
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.